MSAA Debuts New Mobile Website

On October 30, 2013, the Multiple Sclerosis Association of America (MSAA) debuts a new mobile website (accessed at mymsaa.org via a mobile device) to meet the growing needs of individuals with multiple sclerosis (MS) and their care partners. The mobile website allows users to have on-the-go access to many of the resources currently available on MSAA’s desktop website. The mobile website is another example of how MSAA continues to develop initiatives to improve lives today for the entire MS community.

Read News Article

MSAA Featured in USA Today Article

Please read this USA Today article about organizations that help people with obtaining information in regard to the new health exchanges.

Read News Article

The Multiple Sclerosis Association of America Launches New Website Features

The Multiple Sclerosis Association of America (MSAA) is pleased to announce new website additions including an MS Relapse Resource Center and chat feature to its award-winning website, mymsaa.org. As a leading resource for the entire multiple sclerosis (MS) community, MSAA developed these additions to provide easier access to vital information and assistance to individuals with MS, their care partners, and healthcare professionals.

Read News Article

My MS Manager Named One of the Best Multiple Sclerosis Mobile Apps by Healthline

MSAA is pleased to announce that Healthline.com has named MSAA’s My MS Manager™ mobile phone app as one of the top smartphone and tablet applications for the iPhone and Android platforms. Healthline selected the best MS apps based on the potential to assist individuals and their loved ones in a number of ways.

Read News Article

Recent Reports of Adverse Events with Individuals on MS Medications – How to Interpret the Information

Two reports of adverse events have appeared in the media recently. Each referred to an individual with MS who had been taking an MS disease-modifying therapy (DMT) and later became ill or died.

Read News Article

Vaccine Safety and MS

Article summary: Published studies to date continue to affirm the safety of several vaccinations for individuals with MS. These vaccines (listed in this article) do not increase the risk of developing MS or exacerbating its symptoms. The safety of the shingles vaccine is more difficult to judge for individuals with MS, since this is a live-virus vaccine. Vaccines that use a live virus could pose a risk for individuals with compromised immune systems, resulting from an illness or a medication taken for an illness. The shingles vaccine is important for individuals 60 years and older, because the risk of developing shingles, as well as a painful long-term complication of shingles, greatly increases with age. Similar to the shingles vaccine, the yellow fever vaccine also uses a weakened, live virus. In a small study, the yellow fever vaccine was shown to increase MS disease activity. Before receiving any vaccine, individuals with MS should consult their physician to make sure that the specific vaccine and its timing is appropriate for them.

Read News Article

Shingles Overview and Vaccine Safety

Article summary: Shingles is caused by the reactivation of the varicella zoster virus (VZV), which is the same virus that causes varicella (chickenpox). The reactivation of this virus causes a painful rash with clusters of fluid-filled blisters. Postherpetic neuralgia (PHN) is the most common complication of shingles, causing chronic, sometimes excruciating pain. The shingles vaccine (Zostavax®) is recommended for use in people 60 years and older to reduce the risk of shingles. The shingles vaccine is a live, attenuated vaccine, which could be an issue for members of the MS population, as medications that may modulate or suppress the immune system could pose a risk with a live vaccine. Individuals with MS who are considering a shingles vaccine should discuss the risks and benefits with their doctor.

Read News Article

CMSC and ACTRIMS Cooperative Meeting Highlights (2013)

The largest and most comprehensive meeting on multiple sclerosis (MS) care and research in North America took place May 29 through June 1 in Orlando, Florida, combining the 27th Annual Meeting of CMSC and the 18th Annual Meeting of ACTRIMS. This meeting is unique in that it brings together researchers and clinicians from across the spectrum of MS care, including physicians, nurses, physical and occupational therapists, psychologists, social workers, pharmacists, rehabilitation specialists, and advocacy professionals.

Read News Article

Continued Heart Monitoring Advised during and after Novantrone® (mitoxantrone) treatment

It is now known that mitoxantrone can harm your heart’s pumping action. This harm can show up while you are being treated with the medicine or many years later. To be sure it is working well, your heart needs to be tested before you are treated with mitoxantrone and every year thereafter, even after you stop using mitoxantrone. If the testing shows your heart needs some help, the sooner you get treatment, the better for your health.

Read News Article

Multiple Sclerosis Coalition debuts on Facebook and Twitter

Today the Multiple Sclerosis Coalition (MSC) debuts new accounts on Facebook and Twitter that will serve as a “one-stop” source for information on available MS programs and services. Representing the leading organizations in MS research, advocacy, education, and treatment, the MSC will provide information on the individual offerings of member organizations as well as collaborative efforts orchestrated through the Coalition itself. The MSC can be found on Facebook at www.facebook.com/MSCoalition and on Twitter at @MSCoalition.

Read News Article